Oxford University spinout raises another £20 million for vaccine program

16 January 2018
2019_biotech_test_vial_discovery_big

Oxford University spinout Vaccitech has completed a series A financing round, securing £20 million ($27 million) in new money from Google’s venture capital arm GV, Sequoia China, and existing backer Oxford Sciences Innovation.

Based at the Oxford Science Park, the firm is working on a universal flu vaccine and five other vaccine-related products, based on a technology for inducing cellular immune responses using non-replicating viral vectors.

Vaccitech’s universal influenza vaccine is being tested in a Phase IIb efficacy trial, in which 862 people are enrolled in the first year of a two-year study.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology